ADCs combine antibodies with drug payloads for targeted therapy, but complex manufacturing requires monitoring CQAs across multiple entities.
For a few brief nights each year, you get a rare chance to watch a monster blink. The Event Horizon Telescope collaboration ...
Scientists at the Institute of Science Tokyo (Science Tokyo) have successfully realized the highly selective asymmetric 1,6 ...
As drug potency increases, OEB 6 containment is becoming increasingly crucial for safe HPAPI manufacturing, driven by oncology growth, and complex payloads.
Early-phase oncology trials carry substantial scientific and commercial risk in cancer drug development. Getting them right ...
Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion ...
Q4 2025 Earnings Call February 10, 2026 4:30 PM ESTCompany ParticipantsJacquie Ross - Senior Vice President of Treasury ...
Q2 2026 Earnings Call February 4, 2026 9:00 AM ESTCompany ParticipantsDavid Clair - VP of Investor Relations & ...
Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.
The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Henry Boot PLC - Sheffield, England-based construction and property ...
Evogene Ltd. , a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, Systasy Bioscience GmbH, a ...
Advances in artificial intelligence and multimodal data integration are poised to revolutionise cancer diagnostics – but significant challenges remain before these technologies can be routinely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results